Study wrapper · #979
Kisspeptin-54 attenuates acute lung injury in septic mice through AMPK-mediated suppression of NLRP3 inflammasome.
Wang X, Zou Z, Huang H Neuropeptides. 2026.
DOI: 10.1016/j.npep.2026.102639PubMed: 42418889
Editor's note
A mouse study reporting that exogenous kisspeptin-54 was associated with improved survival and reduced sepsis-induced lung injury via AMPK-mediated suppression of the NLRP3 inflammasome. Findings are preclinical and in a non-reproductive context, so they should not be extrapolated to humans. Directly administers a tracked peptide.
Plain-language abstract
In septic mice, kisspeptin-54 was associated with reduced lung injury and inflammation, an effect linked to AMPK signaling.
Related coverage
Weak / none
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54.
Molecular and cellular endocrinologyn=——2026
Weak / none
Kisspeptin-54 confers renal protection in diabetic nephropathy by ameliorating endothelial permeability through ZEB1 inhibition.
Tissue & celln=——2026
Weak / none
Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory axis.
Cytotechnologyn=——2026